Nanoencapsulación de Antirretrovirales en Nanopartículas de poli-(ε-caprolactona) para la Optimización de la Farmacoterapia del Virus de la Inmunodeficiencia Humana (VIH)

SEREMETA KP.; CHIAPPETTA D.A.; SOSNIK A.

Mar del Plata

Workshop; OBI 2011. 2º Workshop on Artificial Organs, Biomaterials and Tissue Engineering; 2011

Facultad de Ingeniería de la Universidad Nacional de Mar del Plata, INTEMA (UNMdP-CONICET) y SLABO.

According to the latest World Health Organization fact sheets, approximately 40 million people are chronically infected with the HIV worldwide. A successful antiretroviral therapy is associated with a dramatic decrease in the Acquired Immunodeficiency Syndrome (AIDS)-associated mortality. Didanosine (ddI), a synthetic purine nucleoside analogue that inhibits the reverse transcriptase, is used in combination with other antiretroviral drugs as a part of the highly active antiretroviral therapy (HAART). DdI quickly undergoes hydrolysis in the stomach to hypoxanthine, an inactive form. Thus, its oral bioavailability is relatively low (20-40%). This poster will present preliminary results on the encapsulation of the drug within poly (є-caprolactone) nanoparticles as an approach to improve its chemical stability and oral bioavailability. Several techniques (e.g., water-in oil-in-oil emulsion/solvent diffusion/evaporation) were assessed to produce the drug-loaded nanoparticles. Sizes were between 200-250 nm as determined by Dynamic Light Scattering. The total ddI payload was measured by HPLC and the morphology analyzed by SEM. Due to its high water solubility the encapsulation of the drug was not easily accomplished. In this context, the most important limitations in the encapsulation process will be also discussed.